Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study

被引：0
|
作者：
Oh, D-Y. [1 ]
Meric-Bernstam, F. [2 ]
Makker, V. [3 ]
Oaknin, A. [4 ]
Banerjee, S. [5 ]
Gonzalez Martin, A. [6 ,7 ]
Jung, K. H. [8 ]
Lugowska, I. [9 ,10 ]
Manso, L. M. [11 ]
Manzano, A. [12 ]
Melichar, B. [13 ]
Siena, S. [14 ]
Stroyakovskiy, D. [15 ]
Fielding, A. [16 ]
Ma, Y. [17 ]
Puvvada, S. D.
Lee, J-Y. [18 ]
机构：
[1] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[2] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[4] Vall dHebron Inst Oncol, Hosp Univ Vall dHebron, Gynaecol Canc Programme, Barcelona, Spain
[5] Royal Marsden NHS Fdn Trust & Inst Canc Res, Gynaecol Unit, London, England
[6] Univ Navarra, Canc Ctr Clin, Med Oncol Dept, Madrid, Spain
[7] Univ Navarra, Canc Ctr Clin, Programme Solid Tumours CIMA, Madrid, Spain
[8] Univ Ulsan, Dept Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea
[9] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Early Phase Clin Trials Unit, Warsaw, Poland
[10] Maria Sklodowska Curie Natl Res Inst & Oncol Ctr, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland
[11] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[12] Hosp Clin San Carlos, Dept Med Oncol, Expt Therapeut Canc UTEC, Madrid, Spain
[13] Palacky Univ, Univ Hosp, Dept Oncol, Med Sch, Olomouc, Czech Republic
[14] Univ Milan, Dept Oncol, Piazza Osped Maggiore, Milan, Italy
[15] Moscow City Oncol Hosp 62, Healthcare Dept, Moscow, Russia
[16] AstraZeneca, Oncol R&D, Gaithersburg, MD USA
[17] AstraZeneca, Oncol R&D, Cambridge, England
[18] Yonsei Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
74MO
引用
收藏
页码：S1494 / S1495
页数：2
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study
    Meric-Bernstam, F.
    Makker, V.
    Oaknin, A.
    Oh, D. Y.
    Banerjee, S.
    Martin, A. Gonzalez
    Jung, K. H.
    Lugowska, I.
    Manso, L. M.
    Manzano, A.
    Melichar, B.
    Siena, S.
    Stroyakovskiy, D.
    Fielding, A.
    Ma, Y.
    Puvvada, S. D.
    Lee, J. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1274
  • [2] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02)
    Meric-Bernstam, Funda
    Kim, Seung Tae
    Parinyanitikul, Napa
    Moreno, Alberto
    Lin, Chia-Chi
    Gornastolev, Dmitry
    Chindaprasirt, Jarin
    Lugowska, Iwona A.
    Stroyakovskiy, Daniil
    Jassem, Jacek
    Harrison, Michelle L.
    Ostwal, Vikas S.
    Michelini, Flavia
    Jung, Lindsey
    Kuptsova-Clarkson, Nataliya
    Puvvada, Soham D.
    Gan, Hui Kong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
    Meric-Bernstam, Funda
    Makker, Vicky
    Oaknin, Ana
    Oh, Do-Youn
    Banerjee, Susana N.
    Martin, Antonio Gonzalez
    Jung, Kyung Hae
    Lugowska, Iwona A.
    Manso, Luis
    Manzano, Aranzazu
    Melichar, Bohuslav
    Siena, Salvatore
    Stroyakovskiy, Daniil
    Anoka, Chiedozie
    Ma, Yan
    Puvvada, Soham D.
    Lee, Jung-Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA3000 - LBA3000
  • [4] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study
    Wysocki, Piotr Jan
    Jung, Kyung Hae
    Oh, Do-Youn
    Doroshow, Deborah Blythe
    Artamonova, Elena
    Mammatas, Lemonitsa
    Su, Po-Jung
    Moiseyenko, Vladimir
    Penkov, Konstantin
    Stroyakovskiy, Daniil
    Bartolome, Jorge
    Siena, Salvatore
    Fielding, Anitra
    Jung, Lindsey
    Michelini, Flavia
    Puvvada, Soham D.
    Makker, Vicky
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
    Meric-Bernstam, Funda
    Makker, Vicky
    Oaknin, Ana
    Oh, Do-Youn
    Banerjee, Susana N.
    Martin, Antonio Gonzalez
    Jung, Kyung Hae
    Lugowska, Iwona A.
    Manso, Luis
    Manzano, Aranzazu
    Melichar, Bohuslav
    Siena, Salvatore
    Stroyakovskiy, Daniil
    Anoka, Chiedozie
    Ma, Yan
    Puvvada, Soham D.
    Lee, Jung-Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17)
  • [6] An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
    Lee, J-Y
    Makker, V.
    Oaknin, A.
    Oh, D-Y
    Anoka, C.
    Jung, L.
    Simoes, J.
    Puvvada, S. D.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S1553 - S1553
  • [7] An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2
    Lee, J-Y.
    Makker, V.
    Oaknin, A.
    Oh, D-y.
    Anoka, C.
    Jung, L.
    Simoes, J.
    Puvvada, S. D.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2024, 35
  • [8] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)
    Oh, Do-Youn
    Lugowska, Iwona A.
    Stroyakovskiy, Daniil
    Jung, Kyung Hae
    Dumas, Olivier
    Penkov, Konstantin
    Dechaphunkul, Arunee
    Oaknin, Ana
    Kim, Seung Tae
    Starling, Naureen
    Chewaskulyong, Busyamas
    Charonpongsuntorn, Chanchai
    Doroshow, Deborah Blythe
    Hsiao, Sheng-Yen
    Hung, Yi-Ping
    Jung, Lindsey
    Kuptsova-Clarkson, Nataliya
    Michelini, Flavia
    Puvvada, Soham D.
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] DESTINY-PanTumor02 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Exploratory biomarker analyses of HER2 expression and gene amplification in tissue and plasma
    Makker, V.
    Lee, J-Y.
    Oh, D-Y.
    Oaknin, A.
    Puvvada, S. D.
    Cecchi, F.
    Mcewen, R.
    Michelini, F.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S239 - S240
  • [10] A phase II, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select HER2-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, F.
    Anoka, C.
    Dobrowolska, A.
    Chaudhry, A.
    Rowbottom, J.
    Gustavson, M.
    Puvvada, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1253 - S1254
12345